Dr Reddys Laboratories (RDY) Gross Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Gross Margin for 15 consecutive years, with 58.7% the latest figure, recorded in Q2 2023.

• Quarterly Gross Margin changed N/A year-over-year to 58.7% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 59.22% (changed N/A YoY) and the FY2026 annual result came in at 52.77%, down 575.0% from the prior year.
• Gross Margin held at 58.7% in Q2 2023 per RDY's latest filing, from 58.69% in the prior quarter.
• Over the last five years, Gross Margin for RDY reached as high as 59.22% in Q3 2022 and fell as low as 51.65% in Q1 2019.
• A 5-year average of 55.55% and a median of 55.07% in 2019 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2019 — Gross Margin tumbled 410 bps — and 2020, when it soared 442 bps.
• Year by year, Gross Margin stood at 54.07% in 2019, then retreated by 1 bps to 53.78% in 2020, then fell by 1 bps to 53.41% in 2021, then gained by 7 bps to 57.24% in 2022, then advanced by 3 bps to 58.7% in 2023.
• According to Business Quant data, Gross Margin over the past three periods registered 58.7%, 58.69%, and 57.24% for Q2 2023, Q1 2023, and Q4 2022 respectively.